Results 261 to 270 of about 172,226 (310)
Some of the next articles are maybe not open access.
Human mast cell proteases and mast cell heterogeneity
Current Opinion in Immunology, 1988Mast cell neutral proteases are distinctive markers of the MC(T) and MC(TC) cells in humans. Measurements of tryptase levels in vivo serve as an overall indicator of mast cell activity. Further research is needed to evaluate the functional role of these proteases as well as each mast cell type in situations related to both health and disease.
J S, Miller, L B, Schwartz
openaire +2 more sources
Advances in Gerontology, 2017
Mast cells (MC) are present in the skin and mucous membranes, lymphoid organs, intestine wall and brain, where they are located close to the blood and lymphatic vessels and nerve terminals. As a source of a large number of biologically active substances, many of which are released quickly into the environment as a result of degranulation process, mast ...
N A, Kutukova +3 more
openaire +2 more sources
Mast cells (MC) are present in the skin and mucous membranes, lymphoid organs, intestine wall and brain, where they are located close to the blood and lymphatic vessels and nerve terminals. As a source of a large number of biologically active substances, many of which are released quickly into the environment as a result of degranulation process, mast ...
N A, Kutukova +3 more
openaire +2 more sources
Mast Cell Pleomorphism: Properties of Intestinal Mast Cells
1987Consistent with their nearly ubiquitous distribution throughout the body, mast cells interact with a variety of cell types and react to numerous environmental stimuli. They can be activated by macrophage (1) and T cell factors (2), by complement fragments, as well as by IgE-allergen interactions.
M, Swieter +4 more
openaire +2 more sources
Giornale Italiano di Dermatologia e Venereologia, 2019
Mast cells (MCs) are a potent proangiogenic factor in tumors, they product several pro-angiogenic factors such as fibroblast growth factor 2 (FGF-2), vascular epithelial growth factor (VEGF), tryptase and chymase. Tryptase is a serine protease classified as α-tryptase and β-tryptase, both produced by MCs.
Giovanni, Paolino +8 more
openaire +2 more sources
Mast cells (MCs) are a potent proangiogenic factor in tumors, they product several pro-angiogenic factors such as fibroblast growth factor 2 (FGF-2), vascular epithelial growth factor (VEGF), tryptase and chymase. Tryptase is a serine protease classified as α-tryptase and β-tryptase, both produced by MCs.
Giovanni, Paolino +8 more
openaire +2 more sources
2007
Mast cells (MCs) are traditionally thought of as a nuisance for its host, for example, by causing many of the symptoms associated with allergic reactions. In addition, recent research has put focus on MCs for displaying harmful effects during various autoimmune disorders.
Gunnar, Pejler +3 more
openaire +2 more sources
Mast cells (MCs) are traditionally thought of as a nuisance for its host, for example, by causing many of the symptoms associated with allergic reactions. In addition, recent research has put focus on MCs for displaying harmful effects during various autoimmune disorders.
Gunnar, Pejler +3 more
openaire +2 more sources
Plastic and Reconstructive Surgery, 2004
Hemangioma is a primary tumor of the microvasculature in which angiogenesis is initially excessive, followed by spontaneous regression of the newly formed vessels, with the cellular parenchyma gradually being replaced with fibrofatty tissue. Mast cells, which are highly heterogenous in terms of their morphology, function, and metabolic products, have ...
Swee T, Tan +3 more
openaire +2 more sources
Hemangioma is a primary tumor of the microvasculature in which angiogenesis is initially excessive, followed by spontaneous regression of the newly formed vessels, with the cellular parenchyma gradually being replaced with fibrofatty tissue. Mast cells, which are highly heterogenous in terms of their morphology, function, and metabolic products, have ...
Swee T, Tan +3 more
openaire +2 more sources
On the Heterogeneity of Mast Cells
Pharmacology, 2008Mast cells from different locations are shown to vary in their histochemical, ultrastructural, cytochemical and functional properties. The clinical consequences of this heterogeneity and possible reasons for its origin are discussed.
openaire +2 more sources
Current Allergy and Asthma Reports, 2016
For half a century, it has been known that the mast cell is the cell responsible for the majority of anaphylactic events. Its mediators, taken as a whole, are capable of producing all of the clinical manifestations of these events. With the discovery of immunoglobulin E (IgE), it was originally felt that the vast majority of anaphylactic episodes were ...
Phil, Lieberman, Lene Heise, Garvey
openaire +2 more sources
For half a century, it has been known that the mast cell is the cell responsible for the majority of anaphylactic events. Its mediators, taken as a whole, are capable of producing all of the clinical manifestations of these events. With the discovery of immunoglobulin E (IgE), it was originally felt that the vast majority of anaphylactic episodes were ...
Phil, Lieberman, Lene Heise, Garvey
openaire +2 more sources
American Journal of Clinical Pathology, 1975
Autopsy of a patient with well-documented myelofibrosis revealed marked proliferation of mast cells associated with areas of bone-marrow and splenic fibrosis. The findings suggest that the local fibrosis represents the healed phase of an inflammatory reaction mediated by mast cells via the release of histamine into the tissue spaces.
W C, Udoji, S A, Razavi
openaire +2 more sources
Autopsy of a patient with well-documented myelofibrosis revealed marked proliferation of mast cells associated with areas of bone-marrow and splenic fibrosis. The findings suggest that the local fibrosis represents the healed phase of an inflammatory reaction mediated by mast cells via the release of histamine into the tissue spaces.
W C, Udoji, S A, Razavi
openaire +2 more sources
Mast Cell–Targeting Therapies in Mast Cell Activation Syndromes
Current Allergy and Asthma ReportsProvide an overview of the expanding landscape of mast cell (MC)-targeting treatments in mast cell activation syndromes (MCAS).Tyrosine-kinase inhibitors (TKIs) targeting wild-type and mutated KIT can efficiently induce MC depletion. Avapritinib and midostaurin can also temper IgE-mediated degranulation.
Sabato, Vito +4 more
openaire +3 more sources